drugset / Trial / NCT00969072
Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.
Timeline
- Start
- 2003-08
- Primary completion
- 2005-02
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dutasteride | Small molecule | 0.05 mg | — |
| Subject | Dutasteride | Small molecule | 0.5 mg | — |
| Subject | Dutasteride | Small molecule | 2.5 mg | — |